Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study-Reference-Cited by-同舟云学术

Trajectories and prognosis after discontinuation of biologics due to remission in psoriasis: A nationwide cohort study

Published:2023-06 Issue:6 Volume:88 Page:1378-1381
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Nielsen Mia-Louise,Thein David,Rasmussen Mads Kirchheiner,Bertelsen Trine,Dam Tomas Norman,Skov Lone,Bryld Lars Erik,Wu Jashin J.,Thomsen Simon Francis,Thyssen Jacob P.,Egeberg Alexander

Publisher

Elsevier BV

Subject

Dermatology

Reference3 articles.

1. Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis – nationwide results from the DERMBIO registry;Egeberg;J Eur Acad Dermatol Venereol,2017

2. Data resource profile: the Danish National Prescription Registry;Pottegård;Int J Epidemiol,2017

3. The Danish National Patient Registry: a review of content, data quality, and research potential;Schmidt;Clin Epidemiol,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adapting the Goeckerman Regimen for Psoriasis Treatment in Kenya: A Case Study of Successful Management in a Resource-Limited Setting;Psoriasis: Targets and Therapy;2024-08

2. Comparison of Drug-Free Remission after the End of Phase III Trials of Three Different Anti-IL-23 Inhibitors in Psoriasis;Dermatology and Therapy;2024-07-29

3. Impact of the pre‐biologic treatment journey on biologic drug survival in psoriasis: A nationwide cohort study;Journal of the European Academy of Dermatology and Venereology;2024-07-25

4. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States;Journal of Dermatological Treatment;2024-05-15

5. Drug Survival of Adalimumab, Secukinumab, and Ustekinumab in Psoriasis as Determined by Either Dose Escalation or Drug Discontinuation during the First 3 Years of Treatment – a Nationwide Cohort Study;Journal of Investigative Dermatology;2023-11